UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Interim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC)

European journal of cancer (1990), 2016-12, Vol.69, p.S103-S103

2016

Volltextzugriff (PDF)

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S60-S60

2015

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of oncology, 2022-04, Vol.33 (4), p.406-415

2022

Volltextzugriff (PDF)

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2016-12, Vol.27 (12), p.2196-2203

2016

Volltextzugriff (PDF)

75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

Annals of oncology, 2022-11, Vol.33, p.S1460-S1461

2022

Volltextzugriff (PDF)

1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

Annals of oncology, 2022-09, Vol.33, p.S1107

2022

Volltextzugriff (PDF)

1526P Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1

Annals of oncology, 2023-10, Vol.34, p.S859-S859

2023

Volltextzugriff (PDF)

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

European journal of cancer (1990), 2020-03, Vol.127, p.150-157

2020

Volltextzugriff (PDF)

Cancer-Specific Mortality of Right- Versus Left-Sided Colorectal Adenocarcinoma: A Surveillance, Epidemiology, and End Results Database Analysis

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.E195-E196

2017

Volltextzugriff (PDF)

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

European journal of cancer (1990), 2019-02, Vol.108, p.17-24

2019

Volltextzugriff (PDF)

504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)

Annals of oncology, 2024-06, Vol.35, p.S201-S201

2024

Volltextzugriff (PDF)

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

Annals of oncology, 2022-09, Vol.33, p.S1103-S1104

2022

Volltextzugriff (PDF)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S623-S624

2023

Volltextzugriff (PDF)

1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma

Annals of oncology, 2021-09, Vol.32, p.S1113-S1114

2021

Volltextzugriff (PDF)

1416P Genomic landscape of late-stage gastric cancer

Annals of oncology, 2021-09, Vol.32, p.S1062-S1063

2021

Volltextzugriff (PDF)

323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3

Annals of oncology, 2024-06, Vol.35, p.S135-S136

2024

Volltextzugriff (PDF)

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

Annals of oncology, 2022-09, Vol.33, p.S1100

2022

Volltextzugriff (PDF)

191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study

Annals of oncology, 2020-11, Vol.31, p.S1313-S1314

2020

Volltextzugriff (PDF)

193P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9

Annals of oncology, 2020-11, Vol.31, p.S1314-S1315

2020

Volltextzugriff (PDF)

129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Annals of oncology, 2023-11, Vol.34, p.S1520-S1521

2023

Volltextzugriff (PDF)

1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial

Annals of oncology, 2023-10, Vol.34, p.S896-S897

2023

Volltextzugriff (PDF)

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Annals of oncology, 2023-10, Vol.34, p.S1315-S1316

2023

Volltextzugriff (PDF)

1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)

Annals of oncology, 2023-10, Vol.34, p.S857-S858

2023

Volltextzugriff (PDF)

1529P First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels

Annals of oncology, 2020-09, Vol.31, p.S941-S942

2020

Volltextzugriff (PDF)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

ESMO open, 2023-04, Vol.8 (2), p.100778-100778, Article 100778

2023

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Interim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC)

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

1526P Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Cancer-Specific Mortality of Right- Versus Left-Sided Colorectal Adenocarcinoma: A Surveillance, Epidemiology, and End Results Database Analysis

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma

1416P Genomic landscape of late-stage gastric cancer

323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study

193P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9

129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)

1529P First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

Suchergebnisse filtern